SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that Dr. Bassam Damaj, President and Chief Executive Officer, will provide company overview presentations at two conferences in San Francisco, CA on Wednesday, January 12, 2011, as follows:
Dr. Damaj noted, "I look forward to presenting the Apricus Bio story at these two, key conferences. During these presentations, I intend to provide a review of corporate activities, including the status of our partnering discussions for Vitaros®, which was recently approved by Health Canada for the treatment of erectile dysfunction, as well as our commercialization plans in additional international markets, and our progress with regard to clinical development of our pipeline product candidates."
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its clinically-validated NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including its approved drug erectile dysfunction treatment, Vitaros, as well as compounds in development from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.
CONTACT: Apricus Biosciences, Inc. Ed Cox, V.P. Investor Relations & Corporate Development (858) 848-4249 ecox@apricusbio.com Rx Communications Group, LLC Apricus Bio Investor Relations: Paula Schwartz, Investor Relations (917) 322-2216 pschwartz@rxir.com